Хроничното възпаление при пациенти на хемодиализа (HD) показва лоша прогноза. Терапевтичните подходи обаче са ограничени. Водородният газ (Н (2)) подобрява окислителните и възпалителни наранявания на органи при животински модели. Разработихме HD система, използваща диализен разтвор с високи нива на разтворен Н (2) и изследвахме клиничните ефекти. Диализният разтвор с Н (2) (средно 48 ppb) се получава чрез смесване на диализатни концентрати и вода с обратна осмоза, съдържаща разтворен Н (2), генерирани чрез техника на водна електролиза. Субектите включват 21 стабилни пациенти със стандартен HD, които са преминали към тест HD за 6 месеца на три сесии седмично. По време на периода на изследване не са наблюдавани неблагоприятни клинични признаци или симптоми. По време на проучването се наблюдава значително намаляване на систолното кръвно налягане (SBP) преди и след диализа, и значителен брой пациенти са постигнали SBP <140 mmHg след HD (изходно ниво, 21%; 6 месеца, 62%; P <0,05). Промените в диализните параметри са минимални, докато са установени значителни понижения в нивата на плазмен моноцитен хемоаттрактант протеин 1 (P <0,01) и миелопероксидаза (P <0,05). Добавянето на Н (2) към хемодиализните разтвори подобрява възпалителните реакции и подобрява контрола на АН.
Тази система може да предложи нова терапевтична опция за контрол на уремия. Добавянето на Н (2) към хемодиализните разтвори подобрява възпалителните реакции и подобрява контрола на АН. Тази система може да предложи нова терапевтична опция за контрол на уремия. Добавянето на Н (2) към хемодиализните разтвори подобрява възпалителните реакции и подобрява контрола на АН. Тази система може да предложи нова терапевтична опция за контрол на уремия.
1 Himmelfarb J, Stenvinkel P, Ikizler TA, et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia, Kidney Int, 2002, vol. 62 (pg. 1524-1538)
2 Sela S, Shurtz-Swirski R, Cohen-Mazor M, et al. Primed peripheral polymorphonuclear leukocyte: a culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease, J Am Soc Nephrol, 2005, vol. 16 (pg. 2431-2438)
3 Zimmermann J, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients, Kidney Int, 1999, vol. 55 (pg. 648-658)
4 Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial, Lancet, 2000, vol. 356 (pg. 1213-1218)
5 Tepel M, van der Giet M, Statz M, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial, Circulation, 2003, vol. 107 (pg. 992-995)
6 Mann JF, Lonn EM, Yi Q, et al. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. HOPE Investigators, Kidney Int, 2004, vol. 65 (pg. 1375-1380)
7 Kendrick J, Chonchol MB. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease, Nat Clin Pract Nephrol, 2008, vol. 12 (pg. 672-681)
8 Ohsawa I, Ishikawa M, Takahashi K, et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals, Nat Med, 2007, vol. 13 (pg. 688-694)
9 Fukuda K, Asoh S, Ishikawa M, et al. Inhalation of hydrogen gas suppresses hepatic injury caused by ischemia/reperfusion through reducing oxidative stress, Biochem Biophys Res Commun, 2007, vol. 361 (pg. 670-674)
10 Nagata K, Nakashima-Kamimura N, Mikami T, et al. Consumption of molecular hydrogen prevents the stress-induced ImpaI/Rments in hippocampus-dependent learning tasks during chronic physical restraint in mice, Neuropsychopharmacology, 2009, vol. 34 (pg. 501-508)
11 Kajiya M, Silva MJ, Sato K, et al. Hydrogen mediates suppression of colon inflammation induced by dextran sodium sulfate, Biochem Biophys Res Commun, 2009, vol. 386 (pg. 11-15)
12 Buchholz BM, Kaczorowski DJ, Sugimoto R, et al. Hydrogen inhalation ameliorates oxidative stress in transplantation induced intestinal graft injury, Am J Transplant, 2008, vol. 8 (pg. 2015-2024)
13 Wood KC, Gladwin MT. The hydrogen highway to reperfusion therapy, Nat Med, 2007, vol. 13 (pg. 673-674)
14 Shirahata S, Kabayama S, Nakano M, et al. Electrolyzed-reduced water scavenges active oxygen species and protects DNA from oxidative damage, Biochem Biophys Res Commun, 1997, vol. 234 (pg. 269-274)
15 Nakayama M, Kabayama S, Terawaki H, et al. Less-oxidative hemodialysis solution rendered by cathode-side application of electrolyzed water, Hemodial Int, 2007, vol. 11 (pg. 322-327)
16 Nakayama M, Kabayama S, Nakano H, et al. Biological effects of electrolyzed water in hemodialysis, Nephron Clin Pract, 2009, vol. 112 (pg. c9-c15)
17 Vita JA, Brennan ML, Gkce N, et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans, Circulation, 2004, vol. 110 (pg. 1134-1139)
19 Baggiolini M. Chemokines and leukocyte traffic, Nature, 1998, vol. 392 (pg. 565-568)
18 Kalantar-Zadeh K, Brennan ML, Hazen SL. Serum myeloperoxidase and mortality in maintenance hemodialysis patients, Am J Kidney Dis, 2006, vol. 48 (pg. 59-68)
20 Pawlak K, Pawlak D, Mysliwiec M. Possible new role of monocyte chemoattractant protein-1 in hemodialysis patients with cardiovascular disease, Am J Nephrol, 2004, vol. 24 (pg. 635-640)
21 Buraczynska M, Bednarek-Skublewska A, Buraczynska K, et al. Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism as a potential risk factor for cardiovascular disease in hemodialyzed patients, Cytokine, 2008, vol. 44 (pg. 361-365)
22 Yoshimura K, Nakano H, Yokoyama K, et al. High iron storage levels are associated with increased DNA oxidative injury in patients on regular hemodialysis, Clin Exp Nephrol, 2005, vol. 9 (pg. 158-163)
23 Maruyama Y, Nakayama M, Yoshimura K, et al. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2′-deoxyguanosine levels, Nephrol Dial Transplant, 2007, vol. 22 (pg. 1407-1412)
24 Wang AY, Lam CW, Yu CM, et al. N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients, J Am Soc Nephrol, 2007, vol. 18 (pg. 321-330)
25 Agarwal R, Sinha AD. Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis, Hypertension, 2009, vol. 53 (pg. 860-866)
26 Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials, Lancet, 2009, vol. 373 (pg. 1009-1015)
27 Agarwal R, Alborzi P, Satyan S, et al. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial, Hypertension, 2009, vol. 53 (pg. 500-507)
28 Fagugli RM, Reboldi G, Quintaliani G, et al. Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients, Am J Kidney Dis, 2001, vol. 38 (pg. 371-376)
29 Kalirao P, Kaplan JM. Nocturnal hemodialysis, Clin Exp Nephrol, 2009, vol. 13 (pg. 257-262)
30 Vaziri ND, Rodriguez-Iturbe B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension, Nat Clin Pract, 2006, vol. 2 (pg. 582-593)
Google ScholarCrossrefWorldCat
31 Vaziri ND, Dicus M, Ho ND, et al. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency, Kidney Int, 2003, vol. 63 (pg. 179-185)
32 Vaziri ND, Ni Z, Oveisi F, et al. Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency, Hypertension, 2002, vol. 39 (pg. 135-141)
33 Huang KC, Yang CC, Lee KT, et al. Reduced hemodialysis-induced oxidative stress in end-stage renal disease patients by electrolyzed reduced water, Kidney Int, 2003, vol. 64 (pg. 704-714)
34 Kikuch K, Tanaka Y, Saihara Y, et al. Concentration of hydrogen nanobubbles in electrolyzed water, J Coll Inter Sci, 2006, vol. 298 (pg. 914-919)
